SP0969:Phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of lacosamide as adjunctive therapy in subjects with epilepsy #4 years to <17 years of age with partial onset seizures

Grants and Contracts Details

StatusFinished
Effective start/end date8/23/138/31/15

Funding

  • UCB Pharma (domestic): $32,639.00